Zacks Investment Research
04 Aug 2026, 13:51 UTC · 9w ago
Impact · against what's priced in
Harmony Biosciences (HRMY) shows strong quarterly performance with a significant earnings beat of 32% and revenue growth to $261.28 million. Despite year-to-date underperformance, the results suggest a recovery in fundamental execution compared to the previous quarter's miss.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Harmony Biosciences reported quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.97.
So whatA significant earnings beat (31.96%) generally triggers positive short-term price action for the specific ticker.
More positive than 79% of claims this week
Harmony Biosciences posted quarterly revenues of $261.28 million, exceeding the consensus estimate by 3.46%.
Continue reading
5 related stories
The company delivered a significant earnings beat of $1.28 per share against a $0.97 estimate and increased revenue to $261.28 million, reversing a negative surprise from the previous quarter.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 54% of claims this week
Harmony Biosciences shares have declined approximately 4.9% year-to-date, underperforming the S&P 500's 11% gain.
More negative than 63% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company beat both earnings and revenue estimates for the quarter with a significant positive earnings surprise.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
4h ago
+7.4%
Price agrees with the score
$38.23 vs $35.60 close before publication (Aug 3) · not market-adjusted
HRMY chart →
